ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2013
Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed, 1 synthesis or guideline pooled it, 258 citations in OpenAlex.
- Anemia and associated factors among women with cancer patients in Ethiopia: A systematic review and meta-analysis.Women's health (London, England)Pooled it
- Prevalence of iron deficiency in patients admitted to a geriatric unit: a multicenter cross-sectional study.BMC geriatrics · 2024Trial
- Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study).The oncologist · 2022Trial
- Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized study.Annals of hematology · 2021Trial
- Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy.Medical oncology (Northwood, London, England) · 2014Trial
- High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients.British journal of haematology · 2026Article
- Characterization of anemia and its association with functional status and depression in geriatric patients with solid organ cancers.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Observational
- Iron overload in the tumor microenvironment induces CD8Nature communications · 2026Article
- Iron deficiency in patients undergoing radiotherapy: Prevalence and clinical characteristics.Clinical and translational radiation oncology · 2026Article
- Iron diminishes immunosuppressive macrophages and enhances anti-PD-1 immunotherapy in breast cancer models.Journal of experimental & clinical cancer research : CR · 2026Article
- High prevalence of iron deficiency and predictive value of nutritional risk scores in critically ill geriatric emergency patients: a prospective cross-sectional study.Scientific reports · 2026Article
- Article
- A prospective study of intravenous iron effectiveness on quality of life and functional outcomes in patients with cancer.Scientific reports · 2026Observational
- Evaluation of anemia and iron status in Japanese patients with gynecological malignancy: retrospective cohort studyBMC women's health · 2025Article
- Expert opinion on the management of anemia in prostate cancer patients receiving PARP inhibitors.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Review
- Iron Deficiency Impairs Muscle Stem Cell Proliferation and Skeletal Muscle Regeneration via HIF-2α Stabilization.Journal of cachexia, sarcopenia and muscle · 2025Article
- Cause-specific mortality among workers in asbestos mining and enrichment factories (Asbest Chrysotile Cohort Study) compared with the general population of Sverdlovsk Oblast, Russian Federation.Journal of occupational medicine and toxicology (London, England) · 2025Article
- Mediation Mendelian randomization study of plasma proteomics reveals the causal relationship and potential mechanisms between iron and colorectal adenocarcinoma.Discover oncology · 2025Article
- Vitamin B12 in Cancer Patients: Clinical Insights into Deficiency, Excess, Diagnosis, and Management.Nutrients · 2025Review
- Evaluation of a Quality-Improvement Initiative to Address Nutritional Anemia in Gynecologic Oncology.O&G open · 2025Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOnly limited data on the prevalence of iron deficiency (ID) and its correlation with clinical parameters are available in cancer. ID frequently contributes to the pathogenesis of anemia in patients with cancer and may lead to several symptoms such as impaired physical function, weakness and fatigue. PATIENTS AND
methodsParameters of iron status and clinical parameters were evaluated in 1528 patients with cancer who presented consecutively within a four-month period at our center. One thousand fifty-three patients had solid tumors and 475 hematological malignancies.
resultsID [transferrin saturation (TSAT) < 20%] was noted in 645 (42.6%) of the 1513 patients with TSAT tests available and 500 (33.0%) were anemic. ID rates were highest in pancreatic (63.2%), colorectal (51.9%) and lung cancers (50.7%). Of the 409 iron-deficient patients in whom serum ferritin levels were available additionally to TSAT, 335 (81.9%) presented with functional ID (FID) (TSAT < 20%, serum ferritin ≥30 ng/ml) and 74 (18.1%) with absolute ID. In patients with solid tumors, prevalence of ID correlated with cancer stage at diagnosis (P = 0.001), disease status (P = 0.001) and ECOG performance status (P = 0.005).
conclusionsID was frequently noted in cancer and was associated with advanced disease, close proximity to cancer therapy, and poor performance status in patients with solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.